<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149837</url>
  </required_header>
  <id_info>
    <org_study_id>BB-IND 14309</org_study_id>
    <nct_id>NCT01149837</nct_id>
  </id_info>
  <brief_title>Evaluation of InnoLIA HTLV I/II Score</brief_title>
  <official_title>In Vitro Diagnostic Study for Supplemental Testing of Anti-HTLV-I/II Reactive Human Blood Specimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creative Testing Solutions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Creative Testing Solutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The InnoLIA HTLV I/II Score is an in vitro diagnostic test for confirmation of antibodies to
      human T-cell lymphotropic virus (HTLV) type I and type II in human blood samples. It is
      intended as a supplemental test for blood donor samples that are reactive in routine
      anti-HTLV screening tests. This study will determine if the test is useful for donor
      counseling purposes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The InnoLIA HTLV I/II Score study consists of three sub-studies. The first sub-study will
      determine the sensitivity, specificity and accuracy of HTLV type assignment using
      well-characterized samples from the NIH-funded HTLV Outcomes Study (HOST). The second
      sub-study will compare automated reading and interpretation of test results with manual
      reading and interpretation using a sub-set of samples tested in the initial study. The third
      sub-study allows for use of the InnoLIA HTLV I/II Score as a supplemental test for whole
      blood and HCT/P donors testing repeatedly reactive with an FDA-approved donor screening test
      for anti-HTLV-I/II.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>INNO-LIA HTLV I/II Score Testing</measure>
    <time_frame>September 2013 through December 2013, up to 3 months</time_frame>
    <description>322 residual donor samples tested</description>
  </primary_outcome>
  <primary_outcome>
    <measure>INNO-LIA HTLV I/II Score Testing</measure>
    <time_frame>January 2014 through December 2014, up to one year</time_frame>
    <description>896 residual donor samples tested</description>
  </primary_outcome>
  <primary_outcome>
    <measure>INNO-LIA HTLV I/II Score Testing</measure>
    <time_frame>January 2015 through December 2015, up to one year</time_frame>
    <description>630 residual donor samples tested</description>
  </primary_outcome>
  <primary_outcome>
    <measure>INNO-LIA HTLV I/II Score Testing</measure>
    <time_frame>January 2016 through May 2016</time_frame>
    <description>315 residual donor samples tested</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4500</enrollment>
  <condition>Human T-Lymphotrophic Virus Type I and/or Type II</condition>
  <arm_group>
    <arm_group_label>residual blood donor samples</arm_group_label>
    <description>Protocol describes testing an HTLV-I/II antibody reactive population from this cohort using the InnoLIA HTLV I/II Score line immunoassay</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InnoLIA HTLV I/II Score line immunoassay</intervention_name>
    <description>This intervention consists of testing a residual serum or plasma sample from a blood donation or donor follow-up sample using the InnoLIA HTLV I/II Score line immunoassay</description>
    <arm_group_label>residual blood donor samples</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      human serum and/or human plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Whole blood and HCT/P donor samples found repeatedly reactive for anti-HTLV-I/II using an
        FDA approved donor screening test
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects completing a health history evaluation for routine donor screening

          -  Subjects willing and able to provide informed consent

          -  Subjects testing repeat reactive on a licensed screening test for HTLV antibodies

        Exclusion Criteria:

          -  Subjects not meeting health history criteria for routine donor screening

          -  Subjects unwilling and unable to provide informed consent

          -  Subjects testing negative on a licensed screening test for HTLV antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip C Williamson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creative Testing Solutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creative Testing Solutions</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>June 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2010</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HTLV</keyword>
  <keyword>HTLV I</keyword>
  <keyword>HTLV II</keyword>
  <keyword>HTLV Type I and/or HTLV Type II antibody</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

